Todd Lynch Joins BioAgilytix Labs As SVP And Chief Financial Officer

DURHAM, N.C.--(BUSINESS WIRE)--BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, has welcomed Todd Lynch, CPA to its executive leadership team as SVP and Chief Financial Officer. With more than 23 years of experience in biotechnology, big pharma, clinical diagnostics, and contract research organizations ranging from pre-revenue to Fortune 500 companies, Mr. Lynch will play a key role in the development and execution of strategies to support BioAgilytix's rapid growth.

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”